Skip to main content
SpringerLink
Log in

Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure

  • Chapter
  • First Online:
ACEi and ARBS in Hypertension and Heart Failure

Part of the book series: Current Cardiovascular Therapy ((CCT,volume 5))

  • 1242 Accesses

Abstract

Blood pressure (BP)-lowering is a cornerstone of cardiovascular risk reduction in patients with hypertension and heart failure (HF). Antihypertensive agents recommended by current international guidelines for such individuals include angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers and diuretic agents. However, as high proportions of patients with HF suffer simultaneously from other co-morbidities such as chronic kidney disease (CKD) and/or diabetes, selection of the appropriate antihypertensive regimen should take into account the specific indications and contraindications of antihypertensive drugs and combinations in patients with CKD as well as the diverse effects of different antihypertensive drug classes on glucose metabolism. ACEIs and ARBs represent the drugs of first choice for patients with diabetic nephropathy or non-diabetic proteinuric kidney disease, but in patients with non-diabetic CKD without proteinuria they have no specific indication. Furthermore, the ACEI and ARB combination was associated with adverse renal effects in recent clinical trials. With regards to the metabolic effects of antihypertensive drugs, older β-blockers and diuretic agents were shown to deteriorate insulin sensitivity and to elevate the risk of new-onset diabetes, while ACEIs and ARBs have neutral or even beneficial impact on glucose metabolism. This chapter will discuss currently available clinical evidence on the effect of antihypertensive treatment on kidney disease progression and on metabolic profile, aiming to offer insights on the choice of the appropriate BP-lowering regimen in patients with HF in the presence of CKD and/or diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–319.

    PubMed  Google Scholar 

  2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–245.

    PubMed  Google Scholar 

  3. Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Arch Intern Med. 2008;168:2481–8.

    PubMed  PubMed Central  Google Scholar 

  4. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994–2003. Arch Intern Med. 2008;168:418–24.

    PubMed  Google Scholar 

  5. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016–22.

    PubMed  Google Scholar 

  6. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.

    PubMed  CAS  Google Scholar 

  7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.

    PubMed  CAS  Google Scholar 

  8. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:1–290.

    Google Scholar 

  9. Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int. 2014;85(3):536–46.

    PubMed  CAS  Google Scholar 

  10. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.

    PubMed  CAS  Google Scholar 

  11. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.

    PubMed  CAS  Google Scholar 

  12. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–7.

    PubMed  CAS  Google Scholar 

  13. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007;25:249–52.

    PubMed  CAS  Google Scholar 

  14. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007;7:191–9.

    PubMed  CAS  Google Scholar 

  15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.

    PubMed  CAS  Google Scholar 

  16. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    PubMed  CAS  Google Scholar 

  17. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.

    PubMed  CAS  Google Scholar 

  18. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828–38.

    PubMed  CAS  PubMed Central  Google Scholar 

  19. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21:922–9.

    PubMed  CAS  Google Scholar 

  20. De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–20.

    PubMed  Google Scholar 

  21. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–7.

    PubMed  Google Scholar 

  22. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.

    Google Scholar 

  23. Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.

    PubMed  CAS  Google Scholar 

  24. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–40.

    PubMed  CAS  Google Scholar 

  25. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.

    PubMed  CAS  Google Scholar 

  26. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165:947–53.

    PubMed  Google Scholar 

  27. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.

    PubMed  CAS  Google Scholar 

  28. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–52.

    PubMed  CAS  Google Scholar 

  29. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202.

    PubMed  CAS  Google Scholar 

  30. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.

    PubMed  CAS  Google Scholar 

  31. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004;24:168–75.

    PubMed  CAS  Google Scholar 

  32. Stafilas PC, Sarafidis PA, Lasaridis AN, Aletras VH, Niakas DA. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. Am J Hypertens. 2005;18:1233–40.

    PubMed  Google Scholar 

  33. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–8.

    PubMed  Google Scholar 

  34. O’Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150:717–24.

    PubMed  Google Scholar 

  35. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33.

    PubMed  CAS  Google Scholar 

  36. de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet. 2006;367:899–900.

    PubMed  Google Scholar 

  37. Mann JF, McClellan WM, Kunz R, Ritz E. Progression of renal disease – can we forget about inhibition of the renin-angiotensin system? Nephrol Dial Transplant. 2006;21:2348–51.

    PubMed  CAS  Google Scholar 

  38. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12–26.

    PubMed  CAS  Google Scholar 

  39. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–46.

    PubMed  CAS  Google Scholar 

  40. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23 Suppl 2:B54–64.

    PubMed  Google Scholar 

  41. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.

    PubMed  CAS  Google Scholar 

  42. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190–8.

    PubMed  CAS  Google Scholar 

  43. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038–45.

    PubMed  CAS  Google Scholar 

  44. Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921–6.

    PubMed  CAS  Google Scholar 

  45. Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia. 2009;52:46–9.

    PubMed  CAS  Google Scholar 

  46. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–4.

    PubMed  CAS  PubMed Central  Google Scholar 

  47. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002;25:95–100.

    PubMed  CAS  Google Scholar 

  48. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–24.

    PubMed  CAS  Google Scholar 

  49. Retraction – combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2009;374:1226.

    Google Scholar 

  50. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.

    PubMed  CAS  Google Scholar 

  51. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372:511–2.

    PubMed  Google Scholar 

  52. Ruilope LM, Segura J, Zamorano JL. New clinical concepts after the ONTARGET trial. Expert Rev Cardiovasc Ther. 2011;9:685–9.

    PubMed  Google Scholar 

  53. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.

    PubMed  CAS  Google Scholar 

  54. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011;6:1025–31.

    PubMed  CAS  PubMed Central  Google Scholar 

  55. Novartis announces termination of ALTITUDE study with Rasilez®/Tekturna® in high-risk patients with diabetes and renal impairment. 4-1-2012. http://www.novartis.com/downloads/newsroom/rasilez-tekturna information-center/20111220-rasilez-tekturna.pdf. Accessed 4 January 2012.

  56. Sarafidis PA, Bakris GL. Addition of renin-inhibitor in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014;15(1):97–8.

    PubMed  Google Scholar 

  57. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1–9.

    PubMed  CAS  Google Scholar 

  58. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000;58:2084–92.

    PubMed  CAS  Google Scholar 

  59. Chrysostomou A, Pedagogos E, MacGregor L, Becker G. Aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256–62.

    PubMed  CAS  Google Scholar 

  60. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106–12.

    PubMed  CAS  Google Scholar 

  61. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–36.

    PubMed  CAS  Google Scholar 

  62. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–42.

    PubMed  CAS  Google Scholar 

  63. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–8.

    PubMed  CAS  Google Scholar 

  64. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–50.

    PubMed  CAS  PubMed Central  Google Scholar 

  65. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012;7:1234–41.

    PubMed  CAS  PubMed Central  Google Scholar 

  66. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.

    PubMed  CAS  Google Scholar 

  67. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    PubMed  CAS  Google Scholar 

  68. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens. 1995;9:137–41.

    PubMed  CAS  Google Scholar 

  69. Prince MJ, Stuart CA, Padia M, Bandi Z, Holland OB. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med. 1988;148:2363–8.

    PubMed  CAS  Google Scholar 

  70. Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–30.

    PubMed  CAS  PubMed Central  Google Scholar 

  71. Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia. 1995;38:853–9.

    PubMed  CAS  Google Scholar 

  72. Hunter SJ, Harper R, Ennis CN, et al. Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension. J Hypertens. 1998;16:103–9.

    PubMed  CAS  Google Scholar 

  73. Hunter SJ, Wiggam MI, Ennis CN, et al. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet Med. 1999;16:482–7.

    PubMed  CAS  Google Scholar 

  74. Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8:351–6.

    CAS  Google Scholar 

  75. Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994;43:455–61.

    PubMed  CAS  Google Scholar 

  76. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489–94.

    PubMed  CAS  Google Scholar 

  77. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.

    PubMed  CAS  Google Scholar 

  78. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955–9.

    PubMed  CAS  Google Scholar 

  79. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–35.

    PubMed  CAS  Google Scholar 

  80. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795–801.

    PubMed  CAS  Google Scholar 

  81. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11:753–7.

    PubMed  CAS  Google Scholar 

  82. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397–403.

    PubMed  CAS  Google Scholar 

  83. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  84. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 1987;17:448–54.

    PubMed  CAS  Google Scholar 

  85. Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y. Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens. 1995;17:1257–68.

    PubMed  CAS  Google Scholar 

  86. Zebekakis P, Kopras A, Lasaridis AN, et al. Α comparative study of the effects of amlodipine and fosinopril on blood pressure and insulin sensitivity in hypertensive patients. J Hypertens. 2003;21:S71.

    Google Scholar 

  87. Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens. 1996;9:323–33.

    PubMed  CAS  Google Scholar 

  88. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens. 1999;12:298–303.

    PubMed  CAS  Google Scholar 

  89. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006;119:S24–30.

    PubMed  Google Scholar 

  90. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993–1002.

    PubMed  CAS  Google Scholar 

  91. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels – a systematic review. Blood Press. 2006;15:135–50.

    PubMed  CAS  Google Scholar 

  92. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6.

    PubMed  PubMed Central  Google Scholar 

  93. Sarafidis PA, Lasaridis AN, Hatzistavri L, Zebekakis P, Tziolas I. The effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients. Rev Clin Pharmacol Pharmacokin (Int Ed). 2004;18:60–6.

    CAS  Google Scholar 

  94. Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55:1159–64.

    PubMed  CAS  Google Scholar 

  95. Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55:1149–54.

    PubMed  CAS  Google Scholar 

  96. Grassi G, Seravalle G, Dell’Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761–9.

    PubMed  CAS  Google Scholar 

  97. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–6.

    PubMed  CAS  Google Scholar 

  98. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–72.

    PubMed  CAS  Google Scholar 

  99. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    PubMed  CAS  Google Scholar 

  100. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.

    Google Scholar 

  101. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting – enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.

    PubMed  CAS  Google Scholar 

  102. Reid CM, Johnston CI, Ryan P, WilLson K, Wing LM. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study. Am J Hypertens. 2003;16:11A.

    Google Scholar 

  103. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.

    PubMed  CAS  Google Scholar 

  104. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.

    PubMed  Google Scholar 

  105. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.

    PubMed  CAS  Google Scholar 

  106. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.

    PubMed  CAS  Google Scholar 

  107. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.

    Google Scholar 

  108. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27:247–55.

    PubMed  Google Scholar 

  109. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–6.

    PubMed  CAS  Google Scholar 

  110. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–65.

    PubMed  CAS  Google Scholar 

  111. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.

    PubMed  CAS  Google Scholar 

  112. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561–72.

    PubMed  CAS  Google Scholar 

  113. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

    PubMed  CAS  Google Scholar 

  114. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405–12.

    PubMed  CAS  Google Scholar 

  115. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563–74.

    PubMed  CAS  Google Scholar 

  116. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592–7.

    PubMed  CAS  Google Scholar 

  117. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–62.

    PubMed  Google Scholar 

  118. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–9.

    PubMed  CAS  Google Scholar 

  119. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, “Hippokration” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Pantelis A. Sarafidis M.D., M.Sc., Ph.D.

  2. Section of Nephrology and Hypertension, 1st Department of Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

    Panagiotis I. Georgianos M.D. & Pantelis E. Zebekakis M.D., Ph.D.

  3. Department of Cardiology, Asklepeion General Hospital, 1 Vas. Pavlou Ave, Voula, Athens, 16673, Greece

    Athanasios J. Manolis M.D., Ph.D.

Authors
  1. Pantelis A. Sarafidis M.D., M.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panagiotis I. Georgianos M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pantelis E. Zebekakis M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Athanasios J. Manolis M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Athanasios J. Manolis M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Cardiology School Federico II University of Naples, Naples, Italy

    Pasquale Perrone Filardi

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sarafidis, P.A., Georgianos, P.I., Zebekakis, P.E., Manolis, A.J. (2015). Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure. In: Perrone Filardi, P. (eds) ACEi and ARBS in Hypertension and Heart Failure. Current Cardiovascular Therapy, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-319-09788-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09788-6_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09787-9

  • Online ISBN: 978-3-319-09788-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation